Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Botulinum toxin E (Primary)
- Indications Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Acronyms LANTERN-1
- Sponsors Bonti
- 16 Jan 2018 Planned End Date changed from 15 Feb 2018 to 30 Apr 2018.
- 16 Jan 2018 Planned primary completion date changed from 30 Nov 2017 to 30 Mar 2018.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting, according to a Bonti media release.